Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company, Caris’s upsized public markets debut is an outlier amid the continuing IPO freeze for clinical-stage biotechs developing new drugs.
The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
Experts in precision medicine provide a broad overview of where we are and where we need to go to make the promise and potential of this sector a reality.
New technologies that enable precision medicine approaches to treating disease are reaching more patients. But panelists speaking at MedCity News’ INVEST Precision Medicine Conference added that advances in technology are happening faster than the ability of hospitals and health systems to keep pace.
On the final day of INVEST Precision Medicine, a panel with Caris Health, CVS Health, and Intermountain Healthcare will share assessments of precision medicine's progress and the outlook for this sector. Also, a panel will highlight non dilutive funding opportunities for startups. Register now!
The conference will include conversations with healthcare industry experts from The Steve & Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Vineti, Ori Biotech, CVS Caremark, Caris Life Sciences, HHS, University City Science Center, and more.
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
Syapse and Caris Life Sciences are combining molecular and genomics data with patient medical record information of up to 100,000 cancer patients each year to build out a huge clinical decision-making tool.